Table 1.
Patient’s characteristics
| Patients’ characteristics | N=88 |
| Median age, years (range) | 60 (27–91) |
| Gender: female/male, n (%) | 45 (51)/43(49) |
| Melanoma AJCC stage | |
| Stage IV, n (%) | 84 (96) |
| Stage IIIC, n (%) | 3 (3) |
| Stage IIIB, n (%) | 1 (1) |
| CNS metastases at baseline, n (%) | 25 (22) |
| BRAF status | |
| Wilde type, n (%) | 57 (65) |
| Mutation, n (%) | 26 (29) |
| NA, n (%) | 5 (6) |
| BMI | |
| Normal weight (18.5<BMI≤24.9), n (%) | 24 (27) |
| Overweight (25<BMI≤29.9), n (%) | 36 (41) |
| Obese (BMI ≥30), n (%) | 28 (32) |
| Line of treatment | |
| First-line treatment, n (%) | 55 (62,5) |
| Second-line treatment, n (%) | 22 (25) |
| Third-line treatment, n (%) | 10 (11,4) |
| Fourth-line treatment, n (%) | 1 (1,1) |
| Response rate at 1° assessment | |
| Complete response, n (%) | 6 (7) |
| Partial response, n (%) | 16 (18) |
| Stable disease, n (%) | 30 (34) |
| Progression disease, n (%) | 36 (41) |
| DCR | 44 (50) |
| ORR | 22 (25) |
| Nivolumab dosage | |
| Flat dose 240 mg, n (%) | 11 (12) |
| Flat dose 480 mg, n (%) | 19 (22) |
| Dose 3 mg/kg, n (%) | 58 (66) |
| LDH level | |
| High | 30 (34) |
| Normal | 33 (38) |
| NA | 25 (28) |
AJCC, American Joint Commission on Cancer; BMI, body mass index; CNS, central nervous system; DCR, disease control rate; LDH, lactate dehydrogenase; NA, not available; ORR, overall response rate.